Key facts
- 858 Therapeutics’s last known valuation is $140.0M.
- It has raised $110.0M across 3 recorded rounds; the latest was Early Stage VC ($25.2M) in Jun 2024.
- Notable investors include Insight Partners (New York), New Enterprise Associates, Alexandria Venture Investments, Mirae Asset Capital, Cormorant Asset Management — 8 tracked in total.
- 858 Therapeutics has filed 3 Form Ds with the SEC since 2020, most recently Jul 2024 ($25.2M sold to 12 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for 858 Therapeutics
Funding rounds
3 roundsAbout 858 Therapeutics
Operator of a biotechnology company intended to discover innovative therapeutics for the treatment of cancers that are resistant to current therapies. The company's platform offers to assess the impact of ribonucleic acid modifying proteins on disease biology and generating a pipeline of small molecules against priority targets, enabling healthcare industry to focus on emerging fields of innate immunity, synthetic lethality and RNA modulation.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2019
- Employees
- 25
- Website
- 8five8tx.com/
- Ownership
- Privately Held (backing)
858 Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in 858 Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on 858 Therapeutics in its N-PORT filings yet. We sweep new filings monthly.